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Abbreviations 45 
DBPCFC   Double blind, placebo-controlled food challenge  46 
ED   Eliciting dose 47 
FAQLQ Food allergy related quality of life questionnaire  48 
FEV1  Forced expiratory volume in 1 second 49 
LOAEL Lowest adverse effect level 50 
OFC  Oral food challenge 51 
PA   Peanut allergy 52 
PAL  Precautionary allergen labelling 53 
PATS  Peanut allergen  threshold study 54 
spIgE  Specific IgE 55 
SPT    Skin prick test 56 
VITAL Voluntary Incidental Trace Allergen Labelling 57 
VSEP  VITAL scientific expert panel 58 
 59 
Capsule summary 60 
The derived ED05 for peanut (1.5mg peanut protein) was given in a single dose to 378 peanut 61 
allergic subjects. Only 8 subjects (2.1%) met predetermined criteria for an objective reaction, 62 
suggesting the derived ED05 could be used as a safe reference dose. 63 
 64 
Clinical Implications  65 
The ED05 for peanut (1.5mg peanut protein) was validated in a multicentre study, using a novel 66 
single dose challenge design, which provides a significant quality of life benefit for parents of 67 
participants and could be adapted to other research or clinical settings. 68 
 69 
Keywords 70 
Eliciting dose (ED), Food Allergy related Quality of Life Questionnaires-(FAQLQ), Single dose, 71 
Peanut thresholds, Oral Food Challenges (OFC), Voluntary Incidental Trace Allergen Labelling 72 
(VITAL). Peanut Allergen Threshold Study (PATS) 73 
 74 
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Abstract  79 
 80 
Background 81 
Eliciting doses (ED) of  allergenic foods can be defined by the distribution of threshold doses for 82 
individuals within a specific population. ED05 is the dose that elicits a reaction in 5% of allergic 83 
subjects. The predicted ED05 for peanut (PN) is 1.5 mg of peanut protein (6 mg whole peanut).  84 
Objective 85 
We sought to validate the predicted peanut ED05 (1.5 mg) with a novel single dose challenge. 86 
Methods  87 
Consecutive eligible peanut allergic children in 3 centres were prospectively invited to participate, 88 
irrespective of previous reaction severity. Predetermined criteria for objective reactions were used 89 
to identify ED05 single dose reactors.  90 
Results   91 
518 children (mean age 6.8 years) were eligible. No significant demographic or clinical differences 92 
were identified between 381(74%) participants and 137 (26%) non-participants or between subjects 93 
recruited at each centre. 378 children (206 male) completed the study. Almost half the group 94 
reported ignoring precautionary allergen labelling. 245 (65%) experienced no reaction to the single 95 
dose of peanut. 67 (18%) reported a subjective reaction without objective findings. 58 (15%) 96 
experienced signs of a mild and transient nature that did not meet the pre-determined criteria. Only 97 
8 subjects (2.1%, 95% CI 0.6%-3.4%) met the pre-determined criteria for an objective and likely 98 
related event.  No child experienced more than a mild reaction, 4 of the 8 received oral 99 
antihistamines only and none received epinephrine. Food allergy related quality of life improved 100 
from baseline to 1 month post challenge regardless of outcome (eta squared = 0.2, p <0.0001). 101 
Peanut SPT, peanut and Ara h 2 spIgE levels were not associated with objective reactivity to PN 102 
ED05.   103 
 104 
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Conclusion 105 
A single administration of 1.5 mg PN protein elicited objective reactions in fewer than the predicted 106 
5% of peanut-allergic subjects. The novel single dose OFC appears clinically safe and patient-107 
acceptable, regardless of the outcome. It identifies the most highly dose-sensitive food allergic 108 
population, not otherwise identifiable using routinely available peanut SPT or spIgE levels but this 109 
single-dose approach has not yet been validated for risk assessment of individual patients.  110 
 111 
 112 
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 114 
 115 
 116 
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 128 
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Introduction 130 
Food allergic individuals are clinically selected to participate in diagnostic or research oral food 131 
challenge (OFC) protocols that use graded, incremental doses administered at short, fixed time 132 
intervals. Subjects who have experienced anaphylaxis are often not offered routine clinical OFC 133 
and may be excluded from research OFC protocols (1). It is generally not possible from graded 134 
protocols to determine whether a reaction has occurred to a discrete threshold dose of the allergenic 135 
food or alternatively has been the result of the cumulative dose consumed by the allergic individual 136 
at the time of reaction.  137 
 138 
The eliciting dose (ED) for a peanut allergic reaction in 5% of the peanut allergic population (ED05) 139 
has been estimated at 1.5 mg of peanut protein (6 mg of whole peanut) based upon the population  140 
distribution of  threshold doses (children and adults) from graded, blinded oral challenges of 750 141 
peanut allergic individuals (2-4).  142 
 143 
This study aims to assess the precision of the predicted ED05 using a single dose challenge (6 mg 144 
peanut = 1.5mg of peanut protein, approximately 1/100th of a peanut kernel) in an unselected group 145 
of peanut-allergic children and to validate the processes used to develop the only existing reference 146 
doses for peanut, which have been based upon the ED01 (which is the dose which elicits reactions in 147 
1% of subjects studied) (2). It is likely that subjects who react only mildly at the ED05 would 148 
tolerate the ED01 at least as well (4). This may assist clinicians, regulators and other stakeholders in 149 
risk management for peanut allergic subjects. 150 
 151 
 152 
 153 
 154 
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Methods 155 
We have already published an in-depth description of the background and methodology of the 156 
PATS study (please see reference 5). Additional details are provided below.  157 
 158 
Recruitment 159 
This multi-centre study involved three geographically diverse teaching centres, set in University-160 
affiliated hospitals, providing local, regional and national allergy services. To minimise recruitment 161 
bias, the protocol required that the study was discussed fully with every potentially suitable child 162 
and family, met during routine medical encounters in clinic or hospital attendances. Families who 163 
chose not to participate were asked to complete a study-specific “non-participant”  questionnaire, 164 
adapted from Osborne et al (6) and to give written informed consent for their routinely available 165 
laboratory data to be examined anonymously in the study.  Inclusion and exclusion criteria are 166 
shown in Table 1.  167 
 168 
Food Allergy related Quality of Life Questionnaires-(FAQLQ)  169 
Validated FAQL-Parental form (FAQL-PF) and FAQL Child form (FAQL-CF) questionnaires were 170 
self-administered prior to OFC (T1) and 1 month after OFC (T2) to assess the impact of this novel 171 
single dose OFC protocol on FAQL (8). FAQL-PF and CF are age appropriate questionnaires that 172 
assess the health related quality of life (HRQL) of children with food allergy. The PF version is 173 
completed by a parent of the food allergic child (0-12 years) and the CF by the child themselves (8-174 
12 years) on a 7-point scale ranging from not at all (1) to extremely (7). It has been found to have 175 
excellent reliability (α > 0.9), and construct, cross-cultural, content and longitudinal validity. A 176 
higher score  on either questionnaire reflects higher burden and  poorer FAQL. A lower score 177 
reflects lower burden/better FAQL. 178 
 179 
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 180 
 181 
Single dose Oral Food Challenge (OFC) 182 
The shelf-stable single-dose challenge cookies were manufactured at University of Nebraska-183 
Lincoln, USA and then distributed to participating clinic centres. Peanut content was determined 184 
using the Neogen ® Veratox ® Quantitative Peanut Allergen Test (Neogen Corporation, Lansing 185 
MI).  This assay was also used to establish a validated mixing method to achieve a homogeneous 186 
incorporation of peanut flour into the formulation as well as determining that all ingredients in the 187 
formulation were below the limit of quantitation (2.5 ppm). The stability of product was established 188 
by meeting acceptable criteria for water activity and microbial load.  To maintain taste and texture 189 
cookies were stored frozen until use. The single-dose cookie (6 mg whole peanut = 1.5 mg peanut 190 
protein) consisted of granulated sugar, brown sugar, all-purpose wheat flour, vegetable shortening, 191 
salt, baking soda and light roast, partially defatted peanut flour (Golden Peanut Company, 192 
Alpharetta, Georgia USA). The cookie was eaten under standard open OFC conditions in hospital. 193 
For subjects allergic to other cookie ingredients (e.g. wheat), the peanut dose of 1.5 mg peanut 194 
protein was administered as the same light roast, partially defatted peanut flour in a vehicle food of 195 
the subject’s choice. Routine OFC monitoring was performed, according to local clinical practice. 196 
Children were observed until 2 hours after OFC if no symptoms and signs were elicited or until 2 197 
hours after such symptoms and signs had resolved, with or without treatment.  198 
Criteria for a positive OFC result.  199 
A highly liberal, inclusive strategy was used to capture clinical data during the OFC. Staff were 200 
encouraged to make extensive notes, recording any physical or behavioural changes observed or 201 
self-reported during the single-dose OFC. Predetermined objective criteria were used because the 202 
ED05 was predicted on the basis of challenge-associated objective responses only (1-4). The prior 203 
agreed upon objective criteria for a positive OFC result occurring within 2 hours of ingestion were: 204 
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3 or more concurrent noncontact urticaria persisting for at least 5 minutes; or perioral or periorbital 205 
angioedema; or rhinoconjunctivitis including sneezing; or diarrhoea; or vomiting (excluding gag 206 
reflex); or anaphylaxis (with evidence of circulatory or respiratory compromise, e.g. persistent 207 
cough, wheeze, change in voice, stridor, difficulty breathing, and collapse) (9). 208 
Subjective symptoms were also recorded, such as: palatal itch, headache, dizziness, bloating, 209 
abdominal pain, cramps, muscle aches, aching joints, anxiety, tension, and agitation. 210 
 211 
Case definition 212 
When the clinical study was completed all co-investigators met in person and reviewed all clinical 213 
comments written by staff in each centre during the study. The above criteria were applied and 214 
cases were designated “objective” or “subjective” and then as having met or not met the 215 
predetermined objective criteria as above.  216 
 217 
Blood test 218 
A blood sample was taken for peanut spIgE component analysis (local hospital laboratories, using 219 
ThermoFisher Immunocaps, according to manufacturer’s instructions) and quantitative peanut-220 
specific IgE fluoroenzyme immunoassays 20 minutes after OFC.  221 
 222 
Sample size estimation 223 
Assuming that the observed proportion of the sample that react to the single dose OFC is 5%, a 224 
sample size of 375 corresponds to a 95% confidence interval for the population proportion with a 225 
lower limit of 3.1% and an upper limit of 7.8% using the properties of the binomial distribution. 226 
The investigators felt that this degree of precision in estimation was sufficient to rule out gross 227 
incompatibility between the predicted and observed proportion of participants reacting to the single 228 
dose.  229 
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Statistics 230 
Data were analysed using SPSS Version 22(IBM, Evanston, Illinois, USA). Two sample t-tests for 231 
continuously valued variables and Pearson’s chi- square test or Fisher’s exact test (for low 232 
prevalences) for binary variables were conducted to determine the extent of any covariate 233 
imbalance between participants and non-participants. Differences in means and proportions 234 
between centres were also examined using similar statistical methods. The impact of the single dose 235 
protocol on FAQL was analysed using multivariable regression analysis.  236 
Partial Eta-squared’ ( ), also known as ‘R-Squared’, was the effect size produced by the 237 
statistical tests used in this study. There are many advantages to including effect size when 238 
reporting significant results. Effect size is not influenced by sample size or number of variables. 239 
While a significant result (p value) shows  whether an effect exists, it does not reflect the size of the 240 
effect. Therefore both the magnitude (effect size) and significance (P value) are essential results to 241 
be reported (10-12). A small effect is less than 0.08, a medium effect is less than 0.24 and a large 242 
effect size is 0.25 and above (11). 243 
 244 
Ethical approval 245 
This Study was approved by Cork University Hospital Research Ethics Committee (ECM 4 g), 246 
Melbourne Royal Children’s Hospital Human Research Ethics Committee (HRECApp 32166A), 247 
and the Partners Human Research Committee (2012P002475). Written, informed parental and 248 
adolescent consent and younger children’s assent (according to local IRB age-related  249 
requirements) were obtained.  250 
 251 
 252 
 253 
Results  254 
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Between October 2013 and February 2015, 518 patients were serially approached for participation 255 
(Figure). One hundred thirty-seven individuals were deemed either ineligible or did not wish to take 256 
part in the study. Three hundred seventy-eight completed the challenge protocol. Three subjects did 257 
not complete the protocol. Comparisons of participants and non-participants in each centre are 258 
shown in Table 2.  Univariate analysis of variance showed no significant age differences between 259 
participants and non-participants ( p = 0.62), controlling for centre location ( p=0.84,). Sixty 260 
percent of the overall sample was male. Twenty-two percent of females approached did not 261 
participate, compared to 30% of males (x²= 6.7, p=0.035). There was no difference in participant 262 
sex between centres (x²= 2.6, p=0.63). 263 
 264 
A significant association was found between entry criteria and study centre location. Twenty-seven 265 
percent of Irish subjects had been diagnosed with peanut allergy by the most stringent criterion 266 
(positive OFC), compared to 11% in Australia and only 2.5% in the US, (p<0.001). However, 267 
diagnostic method did not significantly differ between participants and non-participants (x²= 3.6, 268 
p=0.17) or between sexes (x²= 6.17, p=0.19). 269 
 270 
Reactions to single dose ED05 OFC 271 
381 participants took part in this stage of the study; two were excluded due to incomplete ingestion 272 
of the peanut cookie. One subject was excluded before starting the protocol due to inter-current 273 
illness, evident on clinical examination on the day of study. 378 subjects completed the protocol. 274 
362 subjects (96%) received the single dose in the cookie. The remaining 16 subjects received 275 
peanut flour instead in another vehicle food of their choice.   There were no significant differences 276 
in reaction type between the 362 children who ate the standard cookie and the 16 children who ate 277 
the peanut flour in another vehicle (x²= 2.21, p=0.53). 278 
 279 
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245 subjects showed no reaction to the cookie single dose OFC (Table 3). For 133 subjects, some 280 
comment indicative of a possible reaction was recorded in the written OFC records. Sixty-seven 281 
reported subjective symptoms only. Sixty-six events were considered objective, but 58 of these did 282 
not meet the predetermined criteria. The very mild and transient objective symptoms that did not 283 
meet the predetermined criteria included non-persistent usually single sneeze, non-persistent 284 
usually single cough, small areas of transient erythema, and fewer than 3 hives lasting <5 minutes. 285 
Eight participants experienced objective events that met the predetermined criteria (Table 4). All 286 
eight subjects who met the pre-determined criteria consumed the cookie not an alternative vehicle. 287 
No participant experienced more than a mild reaction; four of the 8 most objectively reacting 288 
subjects were treated with oral antihistamines. No other subject was treated and none received 289 
epinephrine.  290 
 291 
Multivariable regression analysis showed no significant differences for age and centre, reaction 292 
type or participant/ non participant status. The eight subjects who met the predetermined objective 293 
criteria were no different in age to others included in the study (Table 4).  294 
 295 
Study centre and reaction type were not significantly related to diagnostic entry criterion (x²=3.39, 296 
p= 0.76). Subjects’ sex was not significantly related to reaction type (x²=4.76, p= 0.19). 297 
 298 
Univariate analyses showed peanut spIgE, Ara h1, Ara h2, Ara h3, Ara h8, Ara h9 spIgE levels and 299 
total IgE levels had no effect on inclusion criterion met or participant/non-participant status,  300 
(p 0.21 - 0.99)  (Table 5).  Peanut SPT differed between study centre location ( = 0.02, p = 0.03) 301 
with a small effect size (11), but not for reaction type (p=0.25). Irish subjects had the lowest mean 302 
wheal size (M= 9.50 mm, SD= 2.66) and Australia the highest (M=15mm, SD=6.47). No other skin 303 
or blood tests were significant for either type of reaction or location (p>0.05). 304 
2
pη
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
                                                                                                                                              PATS  Hourihane et al             12 
 
 
 305 
Adherence to precautionary labelling at study entry was significantly lower in Australia where 76% 306 
ignore labelling compared to Ireland (33%) and US (36%)  (x2 = 66.21, p<0.001). Proxy and self-307 
reported adherence to precautionary allergen labelling did not significantly change from T1-T2 and 308 
was unaffected by age of child, study centre or diagnostic criteria met (p= 0.82-0.42). 309 
 310 
Food allergy-related quality of life 311 
 Baseline scores (before OFC) in the FAQL-PF predicted likelihood of reporting subjective vs 312 
objective symptoms (after OFC) (p=0.001). In effect, children who later experienced subjective 313 
symptoms to the single dose of peanut had the most adverse impact on FAQL at baseline (Mean 314 
=2.6, SD= 1.4). Those who did not experience any reaction had the best FAQL (lowest burden) at 315 
baseline (Mean= 1.8, SD=1.3). This provides further evidence of the  association between clinical 316 
and psychological factors in food allergy.   317 
 318 
There was a significant main effect for time from T1 to T2 for parent reported proxy FAQL-PF (319 
=0.24, p=0.014), with a medium to large effect size (11), where parents reported an improvement in 320 
FAQL for their children from baseline to 1 month post protocol. There was a significant three-way 321 
interaction between age, sex and time ( = 0.11, p=0.014) with a medium effect size (11). 322 
Regardless of age or sex of child, parents reported improved FAQL at T2. Younger boys 323 
experienced a higher impact, whereas as age increased, parents reported more adverse impact for 324 
girls.  Diagnostic criteria and type of reaction elicited in the single dose study were not significant.  325 
 326 
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Children’s self-reported FAQL-CF also improved from baseline (T1) to 1 month post protocol (T2) 327 
( =0.5, p=0.001) with a very large effect size (11). Again there was no  effect on FAQL by 328 
inclusion criteria met or  type of reaction (p=0.158).  329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
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Discussion 352 
The novel single-dose PATS findings strongly support the safety of the statistically determined 353 
ED05 based upon population dose-distribution modelling (2) for administration to a non-selected 354 
patient population. The protocol was very acceptable to families and was clinically very safe. This 355 
approach offers the opportunity to identify the most dose-sensitive peanut allergic population in a 356 
safe and efficient manner. It could be adapted for other major allergenic foods.  357 
 358 
Population EDs can be estimated by statistical dose-distribution modelling of individual patient 359 
threshold doses (2-4).  ED estimates can vary depending upon the choice of model. The single-dose 360 
PATS approach serves as a useful way to validate the ED estimates and select the best parametric 361 
model.   In this single-dose PATS, the percentage of patients reacting with the predetermined 362 
objective criteria (2.1%) was lower than predicted from the log-normal model (5%; 95% CI of 3.1-363 
7.8%).  Several reasons could explain the observed difference between the predicted 5% versus the 364 
observed 2.1% rate. First, selection bias toward more highly sensitive patients could have occurred 365 
with the 750 peanut-allergic subjects in the modelled dataset as many of the patients included in the 366 
dataset were from tertiary allergy clinics which could contribute to a bias toward a more sensitive 367 
peanut-allergic population (2,3), though this study group of consecutive patients was also recruited 368 
in tertiary centres.  Second, although objective responses were used in the clinics conducting 369 
threshold challenges and the PATS, the objective criteria used to establish the lowest observed 370 
adverse effect level (LOAEL) for some of the patients may not have been as stringent as the criteria 371 
established for the PATS.  In particular and among the mild transient reactions that did not meet the 372 
predetermined objective criteria, 13 additional patients experienced hives (a single hive in 8 cases, 373 
2 hives in 4 cases, and 3 hives in 1 case, all lasting less than the stipulated 5 minutes).  Had these 13 374 
cases been counted as positive response to the single-dose challenge, the reaction rate would have 375 
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been 5.5%.  Given these possibilities, the log-normal model used appears to be reasonable and 376 
appropriately conservative for use in the estimation of EDs for peanut.   377 
 378 
Population modelling of individual threshold doses can be used to establish public health measures 379 
such as the control of precautionary allergen labelling (PAL).  In Australia, a Reference Dose for 380 
peanut of 0.2 mg peanut protein was established from estimates of the ED01 (2).  The ED01 was 381 
selected by the VITAL Scientific Expert Panel (VSEP) because it is predicted to protect 99% of the 382 
peanut-allergic population.  However, based on the mild and transient responses encountered in 383 
PATS, the use of the ED05 as the basis for the peanut Reference Dose would be a more reasonable 384 
and implementable risk management decision.   385 
 386 
PAL abounds in many marketplaces but stakeholders find fault with the approach because use of 387 
PAL bears little relationship to actual risk (13,14). Almost 50% of the study population were 388 
routinely ignoring precautionary labelling.  PATS has validated  the  ED05,  so the medical and food 389 
science communities, manufacturing industry, and public health authorities  should consider 390 
adopting this model. This would assist in establishing an ED05-based  peanut Reference Dose to be 391 
used in quantitative risk assessment to underpin PAL, backed by sound scientific evidence, that 392 
protects the vast majority of the peanut allergic community. 393 
 394 
No centre appeared to have a uniquely more sensitive study population than the other two, 395 
suggesting this protocol and the predetermined criteria used for assessing single dose OFC could be 396 
used in other centres.  Ireland had far more challenge-proven cases than the other centres but lower 397 
average ages than the US centre, and Australian patients had larger peanut SPT and paid less 398 
attention to precautionary advisory labels. These inter-centre demographic and diagnostic 399 
differences did not influence the primary or secondary outcomes of the study. 400 
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The predetermined approach to offer the study to all peanut allergic subjects in 3 distinct 401 
geographical regions, the comparison of characteristics of participants and non-participants, the 402 
permissive entry criteria and the pre-determined conservative case definition combine to address 403 
the most common criticism of OFC studies: How representative of the general peanut allergic 404 
population are the subjects who volunteered? This study showed peanut allergic children in each 405 
centre were broadly similar, that severe reactors were included and, critically, that participants 406 
appeared not to differ clinically from non-participants. While we did not prospectively record 407 
previous reaction severity, all subjects were recruited from referred populations seen for their 408 
peanut allergy in tertiary/national referral centres, so it is likely the representation of the severe end 409 
of the clinical spectrum  of peanut allergy in this study population is at least similar than that 410 
reported peanut allergy norms. 411 
 412 
Limitations of the study  413 
Many of the patients recruited were diagnosed without the gold standard double-blind placebo 414 
controlled food challenge.  However, the intended recruitment strategy was to recruit relatively 415 
unselected but near-certain cases, to capture the whole spectrum of cases, which is often not 416 
included in incremental dose challenge studies. Our data show no differences in demographic 417 
details or serological findings between participant and non-participants or between reactors and 418 
non-reactors or between the 8 most certain objective reactors and other groups. The inclusion and 419 
exclusion criteria appear to have been well constructed, based on established clinical methods used 420 
elsewhere, clinical history and SPT and spIgE levels above determined decision points (7).  421 
 422 
Subjects did not undergo placebo challenges, just an active-dose cookie, given once. Placebo doses 423 
would have required doubling attendances to more than 700 visits and we considered the projected 424 
likelihood of significant reactivity of around 5% in the single dose study did not justify a placebo 425 
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arm. It is notable that 65% of subjects reported no reaction at all to the ED05 cookie, despite 426 
knowing it was an “active” dose. Intentionally liberal documentation of reported symptoms and 427 
having a set of fixed, pre-test criteria for an objective reaction allowed post hoc distinction of 428 
subjective from objective reactors, though relatedness of any reaction to the single dose was 429 
difficult in real time due to  the lack of options normally available in routine OFC,  such as waiting 430 
longer between doses and repeating doses (1,7). Subjective reactors had lower pre-test FAQL than  431 
objective reactors and non-reactors which suggests anxiety may play a role in reports of 432 
mild/subjective reactions at low doses in the community and in DBPCFC (15) and also possibly in 433 
reactions to placebo doses during DBPCFC (16).  434 
 435 
PATS was an assessment of low-dose sensitivity in a population of peanut allergic subjects at a 436 
single time point and further studies are needed to assess both population-level and individual 437 
subjects’ variation in low-dose sensitivity over time. Standard, incremental  DBPCFC  does not 438 
correlate well with reported severity of community reactions (17) and dose is only one variable to 439 
be considered in the difficult assessment of severity of food allergy. (18)  440 
 441 
The PATS study offers a new clinical paradigm and methodology with regards to assessing clinical 442 
risk; this current study may potentially define the 5% of patients who are most dose-sensitive. It 443 
confirms previous findings that validated questionnaires assessing FAQL show patients gain nearly 444 
as much from a “failed” OFC as they do from a “passed” OFC, probably due to decreased 445 
uncertainty about the next and future reactions. (13). This tangible impact could promote adoption 446 
of PATS single dose peanut challenges in units not currently performing diagnostic multi-dose 447 
OFC.  448 
 449 
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The single dose protocol does not replace current clinical food challenges which are critical for 450 
definitive diagnosis of food allergy but would provide extra clinical information of patients’ level 451 
of risk, related to dose, and could help inform consumer choices and physician advice to patients 452 
regarding PAL (14, 15); single dose challenges could be done before starting a progressive clinical 453 
food challenge to identify the most highly sensitive patients and reduce any risks associated with 454 
the use of higher doses used in clinical food challenges. PATS suggests clinical validation of other 455 
allergenic food sources could be addressed in similar studies, where the population dose-456 
distribution has been modelled using sufficient threshold data. Clinicians may be able to use PATS 457 
single dose OFCs widely as they are easier to perform than routine diagnostic OFC or DBPCFC.  458 
 459 
Conclusion 460 
The novel single dose OFC, based upon the statistical dose-distribution analysis of past challenge 461 
trials, is a clinically safe and efficient approach to identify the most highly dose-sensitive 462 
population of food-allergic people and it improves food allergy related quality of life. The 463 
validation of the ED05 will also assist regulators, public health agencies and manufacturers in the 464 
establishment of approaches to allergen management that will protect the vast majority of food-465 
allergic consumers/patients. 466 
 467 
 468 
 469 
 470 
 471 
 472 
 473 
 474 
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Table 1.  Inclusion and Exclusion Criteria  29 
Inclusion Criteria Exclusion Criteria 
Age between one to eighteen years old inclusively. Medically unfit for challenge according to local 
unit OFC guidelines/protocol (e.g. high fever, 
unwell with intercurrent illness) 
 
Evidence of peanut allergy by one of the following; Oral corticosteroids within 14 days prior to 
challenge 
 
History of unequivocal exposure (including accidental) 
and typical acute allergic  reaction within the preceding 2 
years and positive peanut SPT (performed according to 
local clinical protocols) /specific IgE. 
 
Episode of anaphylaxis of any cause in the 4 
weeks prior to challenge  
Positive oral food challenge with peanut performed within 
2 years - either open oral food challenge or DBPCFC 
(Double-blind, placebo-controlled food challenge) 
 
Use of antihistamines within 5 days of oral food 
challenge  
Peanut never ingested, but sensitisation to peanut above 
the 95% positive predictive value (PPV) for clinical 
allergy, i.e. peanut serum IgE  >  to 15kU/L (by CAP 
FEIA) and/or peanut SPT wheal size > to 8mm (7) within 
2 months of the single dose challenge.   
 
Asthma that is not well controlled as demonstrated 
by FEV1 <85% of predicted best. 
 30 
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Table 2. Demographic comparison of participants to non-participants 43 
 Participants Non-Participants 
Cork  Melbourne Boston Cork  Melbourne Boston 
Initial Number  124 126 128 63 24  53 
Sex (%Male) 61% 56.3% 55.5% 60.3% 70.8% 71.7% 
Age (Mean yrs) 6.36 7.63 6.55 6.78 8.54 6.65 
Final Number* 124 126 128 63 24 35 
Inclusion criterion met**:     
Typical reaction<2years 68 60 74 38 12 19 
Positive OFC<2years 43 16 2 8 1 2 
SPT/spIgE > 95% PPVs 13 50 52 17 11 14 
*18 participants in Boston did not wish to participate immediately after initial recruitment and therefore no              44 
diagnostic information was gathered. 45 
** Many subjects met both entry criteria 1 and 2 but only the single one entered in the restricted data file option            46 
is reported here. 47 
 48 
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Table 3  Primary Outcome (reaction to single dose food challenge ) per centre 68 
 69 
 70 
 71 
 72 
 73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
 86 
 87 
 88 
 89 
 Total Cork Melbourne  Boston 
Participants 
Active Eligible Participants 
(completed OFC) 
378 124 126 128 
Outcome Group 
Total  378 124 126 128 
Non-reactors 245 94 65 86 
Reactors 133 30 61 42 
Subjective Reactors  67 19 30 18 
Objective Reactors 
Total Objective 66 11 31 24 
Meeting predetermined criteria  8 1 3 4 
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 Table 4.  Details of 8 subjects who met the predetermined objective reactivity criteria/case definition 91 
Participant 
Number 
Location Age 
(yrs)       
Sex Diagnostic method Peanut  
Wheal 
(mm) 
Peanut 
SpIgE 
kUA/L 
SpIgE 
rArah1 
SpIgE 
Arah2 
Outcome 
35 Ireland 11  
 
Female History of typical 
exposure & reaction & 
positive SPT/ spIgE 
15 69.10 11.20 59.20 Rhinoconjunctivitis  
40 Australia 15 Male History of typical 
exposure & reaction & 
positive SPT/ spIgE 
13 2.06 0.53  1.74 Urticaria  
43 Australia 9 Male History of typical 
exposure & reaction & 
positive SPT/ spIgE 
18 N/A N/A N/A Vomiting  
95 Australia 2 Female Peanut never ingested but 
positive SPT/spIgE> 95% 
PPVs 
13 N/A N/A N/A Vomiting 
31 U.S. 9 Male Peanut never ingested but 
positive SPT/spIgE> 95% 
PPVs 
11 0.36 0.10 0.14 Urticaria  
97 U.S. 2 Male History of typical 
exposure & reaction & 
positive SPT/ spIgE 
N/A  100.00 14.80 100.00 Urticaria 
109 U.S. 1 Male History of typical 
exposure &reaction & 
positive SPT/ spIgE 
N/A  57.70 0.10 49.60 Urticaria 
124 U.S. 4 Male History of typical 
exposure & reaction and 
positive SPT/ spIgE 
N/A 46.70 14.70 16.20 Rhinorrhoea 
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Table 5. Reaction type vs. Mean values for Skin and Blood Tests 92 
 Total 
IgE 
Peanut 
spIgE 
 
Peanut SPT  
Wheal  
(mm) 
rAra h1  
spIgE  
 
 
 
rAra h2 
spIgE 
 
 
rAra h3  
spIgE 
 
rAra h8  
spIgE  
 
 
rAra h9  
spIgE 
 
 
Type of reaction 
(n) 
 
Non-reactor 
(245) 
490.46 28.18 11.69 11.11  22.52 4.88 1.49 0.74 
Subjective 
(67) 
1164.89 46.07 15.23 23.42 32.86 9.33 0.74 0.11 
Objective 
(66) 
1130.80 39.46 13.60 14.87 31.90 3.13 1.21 0.19 
Satisfies pre-
determined 
criteria 
(8) 
290.67 45.99 14.00 8.18 45.03 2.35 0.13 0.31 
 93 
 94 
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Assessed for eligibility (n =518) 
Withdrawn by parent/child (n =116) 
 
No reason given for withdrawal (n=18) 
 
Reason given by parent: 
 Too nervous/worried about serious reaction (n=29). 
 Too busy/no time to participate (n=29). 
 Live too far away from study centre (n=10). 
 Wishes to continue to ignore/adhere labelling (n=8). 
 Child does not want to participate (n=8). 
 Wishes to continue to ignore/adhere labelling & are 
worried about potential reaction (n=7).  
Excluded by clinician (n= 21) 
 
Reason given by clinician: 
 Lost to follow up (n=15). 
 Did not met inclusion criteria (n=6). 
 
Allocation of participants based on eligibility and consent (n=518). 
 
Excluded at start/during protocol by clinician (n=3) 
Reason given by clinician: 
 Child too unwell to start protocol (n =1) 
 Incomplete ingestion of peanut cookie (n=2) 
   
Total number of participants not 
eligible/withdrawn (n=137) 
Total number of participants eligible 
and provided consent (n=381) 
Total number of non-participants at end 
of protocol (n =140) Total number of participants at end of protocol 
(n =378) 
Total number of non-reactions (n=245)  Total number of reactions (n=133) 
Total number of subjective reactions (n=67) Total number of objective reactions 
(n=66). 
 
Total number that met pre-determined objective criteria (n=8). 
